Status:
UNKNOWN
Divestment for Artery-involved Pancreatic Cancer
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University
Conditions:
Pancreatic Cancer
Locally Advanced Pancreatic Cancer
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
Pancreatic cancer is the most lethal malignancy of human being. Surgery is the only potential cure of pancreatic cancer. The invasion of major abdominal arteries is one of the most important factor re...
Eligibility Criteria
Inclusion
- Diagnosed with pancreatic cancer staged at cT4NxM0(AJCC Cancer Staging Manual, 8th Edition) based on contrast enhanced CT\&MRI scan and tumor markers;
- Age \> 18 year and \<80 year;
- Agree to participate in the study with signed informed consent.
Exclusion
- Evidence of metastasis based on physical examination, enhanced CT or enhanced MRI;
- Poor performance status and/or co-morbidity precluding pancreatectomy and chemotherapy;
- Focal vessel narrowing or contour irregularity revealed by radiology examinations;
- Economic situations cannot afford designed treatment.
Key Trial Info
Start Date :
March 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2021
Estimated Enrollment :
122 Patients enrolled
Trial Details
Trial ID
NCT03443921
Start Date
March 1 2018
End Date
March 1 2021
Last Update
February 23 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China, 210029